In:
Alimentary Pharmacology & Therapeutics, Wiley, Vol. 55, No. 11 ( 2022-06), p. 1414-1422
Abstract:
Infantile‐onset inflammatory bowel disease can be caused by defects in interleukin‐10 signalling. The natural history and clinical outcomes of allogeneic haematopoietic stem cell transplantation, medical treatment and surgery have not been thoroughly described. Aims This study evaluates disease progression and clinical outcome in patients with interleukin‐10 signalling deficiency. Methods One hundred and nine patients with interleukin‐10 signalling deficiency were retrospectively reviewed from a single tertiary centre. The Kaplan‐Meier method was applied to calculate probabilities of survival and interval between transplant and stoma closure. Results One hundred and nine patients were reviewed, and 102 patients were included in the survival analysis. One hundred and eight patients were identified with IL10RA mutations, and one patient harboured IL10RB mutation. Seventy‐three patients received haematopoietic stem cell transplantation. The overall survival after transplantation was 64.2% (95% confidence interval, 52.8 to 75.6), and without transplantation, it was 47.5% (95% confidence interval, 14.8 to 80.2, P = 0.47). The median timeframe between transplant and stoma closure was 19.6 months. The probability of survival was significantly lower in patients with perforation ( P 〈 0.001), ileus ( P = 0.038) and without thalidomide treatment ( P 〈 0.001) among patients who did not receive haematopoietic stem cell transplantation. The survival probability was not associated with timeframe between transplant and onset, graft source and genotypes. Conclusions The survival probability was not significantly different between patients with transplantation and the non‐transplanted patients.
Type of Medium:
Online Resource
ISSN:
0269-2813
,
1365-2036
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2003094-0
SSG:
15,3
Bookmarklink